Clinical Trials Browser

Phase 2/3 × Autogenic Training × Clear all

NCT02873559 2024-05-29

PROGRESS

Phase 2/3 Completed

Motor Activity, Multiple Endocrine Neoplasia Type 1, Muscle Weakness